As insulin shortages persist, what diabetes patients can do
Some diabetes patients this year have had trouble finding their preferred insulin brands as major drug manufacturers reported ...
pharmaphorum1mon
Novo Nordisk shadows Lilly with insulin price cut plan
The discount affects several of its older long- and short-acting insulin brands in both vial and pre-filled pen formats, including Levemir and Novolin, which will fall 65%, and the NovoLog and ...
pharmaphorum2d
Sanofi turns the tables on Lilly with biosimilar fast-acting insulin
The FDA approved its short-acting insulin, Fiasp (insulin aspart injection ... safe and effective alternatives to brand name drugs approved through the agency’s abbreviated pathways.” ...
FiercePharma8d
Novo Nordisk slashes prices of additional insulin products but not until 2026
Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...